Terms: = Ovarian cancer AND LCK, YT16, 3932, P06239, ENSG00000182866, p56lck, pp58lck
23 results:
1. A multimodal radiomic machine learning approach to predict the lck expression and clinical prognosis in high-grade serous ovarian cancer.
Zhan F; He L; Yu Y; Chen Q; Guo Y; Wang L
Sci Rep; 2023 Sep; 13(1):16397. PubMed ID: 37773310
[TBL] [Abstract] [Full Text] [Related]
2. lck facilitates DNA damage repair by stabilizing RAD51 and BRCA1 in the nucleus of chemoresistant ovarian cancer.
Dey G; Bharti R; Braley C; Alluri R; Esakov E; Crean-Tate K; McCrae K; Joehlin-Price A; Rose PG; Lathia J; Gong Z; Reizes O
J Ovarian Res; 2023 Jun; 16(1):122. PubMed ID: 37370140
[TBL] [Abstract] [Full Text] [Related]
3. CD55 in cancer: Complementing functions in a non-canonical manner.
Bharti R; Dey G; Lin F; Lathia J; Reizes O
Cancer Lett; 2022 Dec; 551():215935. PubMed ID: 36216147
[TBL] [Abstract] [Full Text] [Related]
4. Pretreatment with lck inhibitors chemosensitizes cisplatin-resistant endometrioid ovarian tumors.
Crean-Tate KK; Braley C; Dey G; Esakov E; Saygin C; Trestan A; Silver DJ; Turaga SM; Connor EV; DeBernardo R; Michener CM; Rose PG; Lathia J; Reizes O
J Ovarian Res; 2021 Apr; 14(1):55. PubMed ID: 33888137
[TBL] [Abstract] [Full Text] [Related]
5. Identification of novel prognosis-related genes in the endometrial cancer immune microenvironment.
Ma J; Zhang JK; Yang D; Ma XX
Aging (Albany NY); 2020 Nov; 12(21):22152-22173. PubMed ID: 33159014
[TBL] [Abstract] [Full Text] [Related]
6. Prognostic factors associated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer.
Ayhan A; Akilli H
Int J Gynaecol Obstet; 2021 Feb; 152(2):202-207. PubMed ID: 33020918
[TBL] [Abstract] [Full Text] [Related]
7. Fertility-sparing surgery and survival among reproductive-age women with epithelial ovarian cancer in 2 cancer registries.
Crafton SM; Cohn DE; Llamocca EN; Louden E; Rhoades J; Felix AS
Cancer; 2020 Mar; 126(6):1217-1224. PubMed ID: 31774553
[TBL] [Abstract] [Full Text] [Related]
8. Dual-platform affinity proteomics identifies links between the recurrence of ovarian carcinoma and proteins released into the tumor microenvironment.
Finkernagel F; Reinartz S; Schuldner M; Malz A; Jansen JM; Wagner U; Worzfeld T; Graumann J; von Strandmann EP; Müller R
Theranostics; 2019; 9(22):6601-6617. PubMed ID: 31588238
[TBL] [Abstract] [Full Text] [Related]
9. PTPN3 expressed in activated T lymphocytes is a candidate for a non-antibody-type immune checkpoint inhibitor.
Fujimura A; Nakayama K; Imaizumi A; Kawamoto M; Oyama Y; Ichimiya S; Umebayashi M; Koya N; Morisaki T; Nakagawa T; Onishi H
Cancer Immunol Immunother; 2019 Oct; 68(10):1649-1660. PubMed ID: 31562536
[TBL] [Abstract] [Full Text] [Related]
10. Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature.
Hinchcliff E; Paquette C; Roszik J; Kelting S; Stoler MH; Mok SC; Yeung TL; Zhang Q; Yates M; Peng W; Hwu P; Jazaeri A
Cancer Immunol Immunother; 2019 Sep; 68(9):1515-1526. PubMed ID: 31515669
[TBL] [Abstract] [Full Text] [Related]
11. Association Between BRCA Status and P53 Status in Breast cancer: A Meta-Analysis.
Peng L; Xu T; Long T; Zuo H
Med Sci Monit; 2016 Jun; 22():1939-45. PubMed ID: 27272763
[TBL] [Abstract] [Full Text] [Related]
12. Survival differences of Asian and Caucasian epithelial ovarian cancer patients in the United States.
Fuh KC; Shin JY; Kapp DS; Brooks RA; Ueda S; Urban RR; Chen LM; Chan JK
Gynecol Oncol; 2015 Mar; 136(3):491-7. PubMed ID: 25455734
[TBL] [Abstract] [Full Text] [Related]
13. Masitinib (AB1010), from canine tumor model to human clinical development: where we are?
Marech I; Patruno R; Zizzo N; Gadaleta C; Introna M; Zito AF; Gadaleta CD; Ranieri G
Crit Rev Oncol Hematol; 2014 Jul; 91(1):98-111. PubMed ID: 24405856
[TBL] [Abstract] [Full Text] [Related]
14. Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125.
Patankar MS; Jing Y; Morrison JC; Belisle JA; Lattanzio FA; Deng Y; Wong NK; Morris HR; Dell A; Clark GF
Gynecol Oncol; 2005 Dec; 99(3):704-13. PubMed ID: 16126266
[TBL] [Abstract] [Full Text] [Related]
15. Antitumour activity of the silybin-phosphatidylcholine complex, IdB 1016, against human ovarian cancer.
Gallo D; Giacomelli S; Ferlini C; Raspaglio G; Apollonio P; Prislei S; Riva A; Morazzoni P; Bombardelli E; Scambia G
Eur J Cancer; 2003 Nov; 39(16):2403-10. PubMed ID: 14556934
[TBL] [Abstract] [Full Text] [Related]
16. Modulation of TcR/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patients.
Taylor DD; Bender DP; Gerçel-Taylor C ; Stanson J; Whiteside TL
Br J Cancer; 2001 Jun; 84(12):1624-9. PubMed ID: 11401315
[TBL] [Abstract] [Full Text] [Related]
17. Preclinical oral antitumor activity of BMS-185660, a paclitaxel derivative.
Rose WC; Lee FY; Golik J; Kadow J
Cancer Chemother Pharmacol; 2000; 46(3):246-50. PubMed ID: 11021743
[TBL] [Abstract] [Full Text] [Related]
18. Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy.
Bukowski RM; Rayman P; Uzzo R; Bloom T; Sandstrom K; Peereboom D; Olencki T; Budd GT; McLain D; Elson P; Novick A; Finke JH
Clin Cancer Res; 1998 Oct; 4(10):2337-47. PubMed ID: 9796963
[TBL] [Abstract] [Full Text] [Related]
19. Preclinical antitumor activity of water-soluble paclitaxel derivatives.
Rose WC; Clark JL; Lee FY; Casazza AM
Cancer Chemother Pharmacol; 1997; 39(6):486-92. PubMed ID: 9118459
[TBL] [Abstract] [Full Text] [Related]
20. Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma.
Rabinowich H; Suminami Y; Reichert TE; Crowley-Nowick P; Bell M; Edwards R; Whiteside TL
Int J Cancer; 1996 Nov; 68(3):276-84. PubMed ID: 8903466
[TBL] [Abstract] [Full Text] [Related]
[Next]
